{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T22:17:47Z","timestamp":1793053067180,"version":"4.5.0"},"reference-count":14,"publisher":"American Medical Association (AMA)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Cardiol"],"published-print":{"date-parts":[[2026,3,1]]},"abstract":"\n Importance<\/jats:title>\n Older age is a strong risk factor for bleeding with currently available anticoagulants. Factor XI (FXI) inhibition may offer a safer anticoagulant strategy in this population.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To evaluate the safety of the novel FXI inhibitor abelacimab vs rivaroxaban by age in patients with atrial fibrillation (AF).<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n The randomized clinical trial AZALEA-TIMI 71 randomized patients with AF to receive 1 of 2 subcutaneous abelacimab doses (90 mg or 150 mg monthly) or oral rivaroxaban (20 mg daily, dose reduction to 15 mg). This prespecified analysis of the phase 2b AZALEA-TIMI 71 trial evaluated bleeding risk by age, analyzed continuously and categorically (&amp;lt;75 vs \u226575 years). The trial was conducted from March 2021 to September 2023; data analysis was performed from February to May 2025.<\/jats:p>\n <\/jats:sec>\n \n Interventions<\/jats:title>\n Monthly subcutaneous abelacimab (90 or 150 mg) or daily oral rivaroxaban (20\/15 mg).<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n The primary end point was the composite of major or clinically relevant nonmajor (CRNM) bleeding.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Among 1287 patients randomized, 715 (55.6%) were male and 572 (44.4%) were female; there were 625 patients (49%) 75 years or older. Compared with younger patients, those 75 years or older had lower body mass index (28 vs 32), were less likely to be taking antiplatelet therapy at baseline (17% vs 32%), and were more likely to have creatinine clearance 50 mL\/min or less (33% vs 8%). Both abelacimab doses were associated with significantly less major or CRNM bleeding compared with rivaroxaban in those 75 years or older (hazard ratio [HR], 0.32; 95% CI, 0.17-0.60; and HR, 0.40; 95% CI, 0.22-0.73; for abelacimab, 90 and 150 mg, vs rivaroxaban, respectively) and in those younger than 75 years (HR, 0.28; 95% CI, 0.12-0.61; and HR, 0.35; 95% CI, 0.17-0.70;\n P<\/jats:italic>\n for interaction, .85 and .84, respectively). Patients 75 years or older tended to derive greater absolute risk reductions with abelacimab (7.1 and 6.2 per 100 patient-years for abelacimab, 90 and 150 mg, vs rivaroxaban, respectively) than those younger than 75 years (4.7 and 4.2 per 100 patient-years, respectively). When modeled continuously, bleeding risk tended to increase with age in the rivaroxaban group but remained stable in the abelacimab group (\n P<\/jats:italic>\n for interaction, .33).\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n This study found that abelacimab consistently reduced bleeding compared with rivaroxaban regardless of age, with the potential for a greater absolute reduction in bleeding with older age. FXI inhibition with abelacimab may become a particularly attractive option in older patients with AF and higher bleeding risk. The results of ongoing phase 3 trials are necessary to establish the efficacy and benefit-to-risk ratio of abelacimab.<\/jats:p>\n <\/jats:sec>\n \n Trial Registration<\/jats:title>\n \n ClinicalTrials.gov Identifier:\n NCT04755283<\/jats:ext-link>\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamacardio.2025.5418","type":"journal-article","created":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T16:30:38Z","timestamp":1770222638000},"page":"298","source":"Crossref","is-referenced-by-count":2,"title":["Abelacimab vs Rivaroxaban in Older Individuals With Atrial Fibrillation"],"prefix":"10.1001","volume":"11","author":[{"given":"Samer","family":"Al Said","sequence":"first","affiliation":[{"name":"TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women\u2019s Hospital and Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siddharth M.","family":"Patel","sequence":"additional","affiliation":[{"name":"TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women\u2019s Hospital and Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert P.","family":"Giugliano","sequence":"additional","affiliation":[{"name":"TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women\u2019s Hospital and Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Morrow","sequence":"additional","affiliation":[{"name":"TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women\u2019s Hospital and Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erica L.","family":"Goodrich","sequence":"additional","affiliation":[{"name":"TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women\u2019s Hospital and Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabina A.","family":"Murphy","sequence":"additional","affiliation":[{"name":"TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women\u2019s Hospital and Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce","family":"Hug","sequence":"additional","affiliation":[{"name":"Anthos Therapeutics, Inc, Cambridge, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanobar","family":"Parkar","sequence":"additional","affiliation":[{"name":"Anthos Therapeutics, Inc, Cambridge, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shih-Ann","family":"Chen","sequence":"additional","affiliation":[{"name":"Heart Rhythm Center, Taipei Veterans General Hospital, Cardiovascular Center, Taichung Veterans Hospital, and Cardiovascular Center, China Medical University Hospital, National Yang Ming Chiao Tung University, National Chung Hsing University, and China Medical University, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaun G.","family":"Goodman","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Medicine, St Michael\u2019s Hospital, Unity Health Toronto, and Peter Munk Cardiac Centre, University Health Network, University of Toronto, Toronto, Ontario, Canada"},{"name":"Canadian VIGOUR Centre, University of Alberta, Edmonton, Alberta, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boyoung","family":"Joung","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert G.","family":"Kiss","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Central Hospital of Northern Pest-Military Hospital, Heart and Vascular Center, Semmelweis University, Budapest, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wojciech","family":"Wojakowski","sequence":"additional","affiliation":[{"name":"Division of Cardiology and Structural Heart Diseases, Medical University of Silesia, Katowice, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey I.","family":"Weitz","sequence":"additional","affiliation":[{"name":"Thrombosis and Atherosclerosis Research Institute, Hamilton Health Sciences, and McMaster University, Hamilton, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Bloomfield","sequence":"additional","affiliation":[{"name":"Anthos Therapeutics, Inc, Cambridge, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc S.","family":"Sabatine","sequence":"additional","affiliation":[{"name":"TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women\u2019s Hospital and Harvard Medical School, Boston, Massachusetts"},{"name":"Deputy Editor, JAMA Cardiology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian T.","family":"Ruff","sequence":"additional","affiliation":[{"name":"TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women\u2019s Hospital and Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"9586","key":"hbr250025r1","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/S0140-6736(07)61233-1","article-title":"Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial.","volume":"370","author":"Mant","year":"2007","journal-title":"Lancet"},{"issue":"21","key":"hbr250025r2","doi-asserted-by":"publisher","first-page":"2363","DOI":"10.1161\/CIRCULATIONAHA.110.004747","article-title":"Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the Randomized Evaluation of Long-Term Anticoagulant Therapy (RE-LY) trial.","volume":"123","author":"Eikelboom","year":"2011","journal-title":"Circulation"},{"issue":"2","key":"hbr250025r3","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1161\/CIRCULATIONAHA.113.005008","article-title":"Efficacy and safety of rivaroxaban compared with warfarin among elderly patients with nonvalvular atrial fibrillation in the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF).","volume":"130","author":"Halperin","year":"2014","journal-title":"Circulation"},{"issue":"28","key":"hbr250025r4","doi-asserted-by":"publisher","first-page":"1864","DOI":"10.1093\/eurheartj\/ehu046","article-title":"Efficacy and safety of apixaban compared with warfarin according to age for stroke prevention in atrial fibrillation: observations from the ARISTOTLE trial.","volume":"35","author":"Halvorsen","year":"2014","journal-title":"Eur Heart J"},{"issue":"5","key":"hbr250025r5","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.116.003432","article-title":"Efficacy and safety of edoxaban in elderly patients with atrial fibrillation in the ENGAGE AF-TIMI 48 trial.","volume":"5","author":"Kato","year":"2016","journal-title":"J Am Heart Assoc"},{"issue":"10333","key":"hbr250025r6","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1016\/S0140-6736(22)00456-1","article-title":"Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study.","volume":"399","author":"Piccini","year":"2022","journal-title":"Lancet"},{"issue":"6","key":"hbr250025r7","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1055\/a-2043-0346","article-title":"Factor XI inhibitors in early clinical trials: a meta-analysis.","volume":"123","author":"Galli","year":"2023","journal-title":"Thromb Haemost"},{"issue":"13","key":"hbr250025r8","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1182\/blood-2018-10-880849","article-title":"MAA868, a novel FXI antibody with a unique binding mode, shows durable effects on markers of anticoagulation in humans.","volume":"133","author":"Koch","year":"2019","journal-title":"Blood"},{"issue":"4","key":"hbr250025r9","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1056\/NEJMoa2406674","article-title":"Abelacimab versus rivaroxaban in patients with atrial fibrillation.","volume":"392","author":"Ruff","year":"2025","journal-title":"N Engl J Med"},{"issue":"11","key":"hbr250025r10","doi-asserted-by":"publisher","first-page":"2119","DOI":"10.1111\/jth.13140","article-title":"Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: communication from the SSC of the ISTH.","volume":"13","author":"Kaatz","year":"2015","journal-title":"J Thromb Haemost"},{"issue":"3","key":"hbr250025r11","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1161\/CIRCULATIONAHA.114.013267","article-title":"Efficacy and harms of direct oral anticoagulants in the elderly for stroke prevention in atrial fibrillation and secondary prevention of venous thromboembolism: systematic review and meta-analysis.","volume":"132","author":"Sharma","year":"2015","journal-title":"Circulation"},{"issue":"1","key":"hbr250025r12","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1161\/CIR.0000000000001193","article-title":"2023 ACC\/AHA\/ACCP\/HRS guideline for the diagnosis and management of atrial fibrillation: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines.","volume":"149","author":"Joglar","year":"2024","journal-title":"Circulation"},{"issue":"4","key":"hbr250025r13","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1161\/CIRCULATIONAHA.121.056355","article-title":"Direct oral anticoagulants versus warfarin in patients with atrial fibrillation: patient-level network meta-analyses of randomized clinical trials with interaction testing by age and sex.","volume":"145","author":"Carnicelli","year":"2022","journal-title":"Circulation"},{"issue":"4","key":"hbr250025r14","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1093\/europace\/euac123","article-title":"EHRA expert consensus document on the management of arrhythmias in frailty syndrome, endorsed by the Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), Latin America Heart Rhythm Society (LAHRS), and Cardiac Arrhythmia Society of Southern Africa (CASSA).","volume":"25","author":"Savelieva","year":"2023","journal-title":"Europace"}],"container-title":["JAMA Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamacardiology\/articlepdf\/2844582\/jamacardiology_al_said_2026_br_250025_1773061342.41691.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T15:00:49Z","timestamp":1773241249000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamacardiology\/fullarticle\/2844582"}},"subtitle":["A Prespecified Analysis of the Phase 2b AZALEA-TIMI 71 Trial"],"short-title":[],"issued":{"date-parts":[[2026,3,1]]},"references-count":14,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamacardio.2025.5418","relation":{},"ISSN":["2380-6583"],"issn-type":[{"value":"2380-6583","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3,1]]}}}